
Jounce Therapeutics
A clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients.
Market cap
$97.9m
Enterprise value
($82m)
Share price
$1.88 JNCE
Recent deals
Authorizing premium user...